Membership: Medical registration amounted to 41.0 M members at December 31, 2019, a raise of 1.1 M, or 2.7 percent, from December 31, 2018. Government Business enrollment increased by 854 thousand lives as the Company experienced development in Medicaid and Medicare.
During the fourth quarter of 2019, medical registration increased sequentially by 16 thousand lives, reflecting growth in the Local Group, National, and Medicare companies.
Operating Revenue: Operating revenue was $27.1 B in the fourth quarter of 2019, a raise of $3.8 B, or 16.4 percent, versus the previous year quarter. The increase in operating profits reflected greater premium profits from membership growth throughout our services and rate increases to cover total expense trends. The boost in operating earnings was additional driven by growth in our value-added services, including our drug store and integrated health offerings, partially offset by the 1 year waiver of the health insurance coverage tax in 2019.
Advantage Expense Ratio: The advantage cost ratio was 89.0 percent in the fourth quarter of 2019, a raise of 220 basis points from 86.8 percent in the previous year quarter. The increase, as foreseeable, was mostly driven by the 1 year waiver of the medical insurance tax in 2019.
Medical claims reserves developed at December 31, 2018 established in line with the Companys expectations during 2019.
Medical Cost Trend: For the full year 2019, Local Group medical cost trend was about 6.0%. The Company prepares for Local Group medical cost pattern will be in the range of 4.0% +/- 50 basis points in 2020, consisting of the benefit of enhanced drug store expense from the launch of IngenioRx and other medical expense management initiatives.
Days in Claims Payable: Days in Claims Payable was 38.0 days as of December 31, 2019, a decrease of 1.8 days from September 30, 2019, however a raise of 1.8 days as contrast to December 31, 2018.
SG&A Expense Ratio: The SG&An expense ratio was 12.9 percent in the fourth quarter of 2019, a reduction of 260 basis points from 15.5 percent in the 4th quarter of 2018. The reduction, as predictable, was mainly driven by development in operating earnings and the one year waiver of the health insurance coverage tax in 2019.
Running Cash Flow: Operating capital in the fourth quarter of 2019 was $1.3 B, or 1.4 times earnings, which represents a raise of $864M contrast to the fourth quarter of 2018. Running cash flow was $6.1 B, or 1.3 times earnings for the year ending December 31, 2019.
Share Repurchase Program: During the 4th quarter of 2019, the Company redeemed 1.2 M shares of its regular stock for $306M, or a weighted typical cost of $260.87. For the full year, the Company redeemed 6.3 M shares of its stock for $1.7 B, or a weighted typical price of $268.65. Since December 31, 2019, the Company had about $3.8 B of Board-accepted share repurchase permission remaining.
Money Dividend: During the 4th quarter of 2019, the Company paid a quarterly dividend of $0.80 per share, representing a distribution of cash totaling $202M.
On January 28, 2020, the Audit Committee reported a first quarter 2020 dividend to investors of $0.95 per share, showing a raise of 18.8 percent from the previous quarterly dividend. On an annualized basis, this relates to a dividend of $3.80 per share. The very first quarter dividend is payable on March 27, 2020 to shareholders of record at the close of company on March 16, 2020.
Financial investment Portfolio & & Capital Position: During the 4th quarter of 2019, the Company recorded net realized gains of $24M and other-than-temporary disability losses totaling $17M. Throughout the fourth quarter of 2018, the Company tape-recorded net realized losses of $185M and other-than-temporary disability losses amounting to $8M.
As of December 31, 2019, the Companys net unrealized gain position in the financial investment portfolio was $673M, consisting of fixed maturity securities. As of December 31, 2019 cash and financial investments at the moms and dad company amounted to about $2.7 B.
Its earnings revenues share (EPS) expected to touch remained 38.00% for this year while earning making share for the next 5-years is expected to reach at 17.10%.
Anthem, Inc. (ANTM) stated 4th quarter and complete year monetary 2019 results that reflect double-digit leading and bottom line development and the successful launch of IngenioRx. “Anthem provided strong outcomes to liquidate 2019 featuring the effective launch of IngenioRx, in addition to our biggest organic risk-based growth in over a years,” specified Gail K. Boudreaux, President and CEO. “We have strong momentum moving into 2020 and we will continue to deliver on our dedications to all those we serve.”
Share Repurchase Program: During the fourth quarter of 2019, the Company redeemed 1.2 M shares of its ordinary stock for $306M, or a weighted typical price of $260.87. As of December 31, 2019, the Company had about $3.8 B of Board-accepted share bought authorization staying.
As of December 31, 2019 money and financial investments at the moms and dad business totaled about $2.7 B.
Its earnings revenues share (EPS) expected anticipated touch remained 38.00% for this year while earning making share for the next 5-years is expected to reach at 17.10%.
The stock negotiated 1413730 shares during most recent day nevertheless it has an average volume of 1428.81 K shares. The company has 254.15 M of outstanding shares and 252.96 M shares were floated in the market.
The stock transacted 1413730 shares throughout most current day nevertheless it has a typical volume of 1428.81 K shares. The business has 254.15 M of impressive shares and 252.96 M shares were floated in the market.